- AU$2.83bn
- AU$2.78bn
- $17.20m
- 55
- 26
- 77
- 54
Annual cashflow statement for Mesoblast, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
C2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 6.21 | 10 | 9.39 | 12.4 | 10.2 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -101 | -65.8 | -63.3 | -48.5 | -50 |
| Capital Expenditures | -1.65 | -0.157 | -0.264 | -0.271 | -0.68 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | -0.075 | 0.07 | 0.174 | 0.8 |
| Sale/Maturity of Investment | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.65 | -0.232 | -0.194 | -0.097 | 0.12 |
| Financing Cash Flow Items | -7.77 | -11.8 | -11.5 | -11.6 | -10.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 109 | -9.87 | 74.5 | 40.3 | 147 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.55 | -76.4 | 10.9 | -8.36 | 98.6 |